Anuh Pharma Limited (506260) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Anuh Pharma Limited stock ₹30.19, price ₹81.67, that is 63.0% below the price, quality 57 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Anuh Pharma Limited
506260 · BSEFar too expensive (fair value 63% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range ₹37.84 – ₹126.96 · fair‑value band ₹27.94 – ₹38.64 · the ₹81.67 price screens above the ₹30.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Anuh Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Anuh Pharma Limited manufactures and sells pharmaceuticals, medicinal chemicals, and botanical products in India. The company offers active pharmaceutical ingredients, such as macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, and expectorant, quinolones, and intermediates.
Show moreShow less
It also provides corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, and anti-histamines. The company also exports its products. Anuh Pharma Limited was founded in 1960 and is headquartered in Mumbai, India.
Stock analysis
Anuh Pharma Limited (506260) currently trades at ₹81.67, while our model-based Fair Value estimate is ₹30.19, 63% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹84.67 per share, and 6 of the 17 models we run sit above the ₹81.67 price.
Bear case: the Dividend Discount group reads lowest at ₹14.94, and 11 of the 17 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹27.94 (bear) to ₹38.64 (bull), the price of ₹81.67 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Anuh Pharma Limited reported revenue of ₹7.7B in FY2026 versus ₹4.9B in FY2022, a compound +12.2%/yr. Reported net income was ₹410M in FY2026, compounding +7.7%/yr from FY2022.
Key figures
Market cap ₹8.2B (≈ $87.2M) Micro · P/E ratio 26.0 · P/S ratio 2.11 · EPS (TTM) ₹5.75 · Dividend yield 3.4% · Net margin 7.4% · Return on equity 16.4% · Return on assets (EBIT) 11.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −63%, 506260 screens richer than that median.
Fair Value models
All 17 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
506260 screens overvalued: fair value 63% below the price. Compare with GENNEX →
Compare Anuh Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)Health Care · 2776 stocks
Valuation Multiplesvs Health Care median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| GENNEX GENNEX | ₹9.07 | ₹14.68 | +62% | vs 506260 |
| UnitedHealth Group UNH | $412.02 | $532.82 | +29% | vs 506260 |
| Novartis AG NOVN | CHF 135.76 | CHF 123.08 | −9% | vs 506260 |
| Merck & Co MRK | $144.46 | $129.26 | −11% | vs 506260 |
| AbbVie Inc ABBV | $294.55 | $259.62 | −12% | vs 506260 |
| Roche Holding RO | CHF 414.20 | CHF 326.56 | −21% | vs 506260 |
| CORALAB CORALAB | ₹622.55 | ₹468.58 | −25% | vs 506260 |
| BERLDRG BERLDRG | ₹24.59 | ₹15.48 | −37% | vs 506260 |
| Johnson & Johnson, JNJ | $282.55 | $169.03 | −40% | vs 506260 |
| Eli Lilly and Company LLY | $1,432 | $749.92 | −48% | vs 506260 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Anuh Pharma Limited (506260) overvalued or undervalued?
What is the fair value of 506260?
What is the quality score of 506260?
What is the price target for Anuh Pharma Limited (506260)?
What is the Anuh Pharma Limited stock forecast for 2026?
What is the revenue of Anuh Pharma Limited (506260)?
Does Anuh Pharma Limited pay a dividend?
How much is the dividend of Anuh Pharma Limited (506260)?
What is the intrinsic value of Anuh Pharma Limited (506260)?
Is Anuh Pharma Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 506260?
How much is Anuh Pharma Limited worth?
What do the bullish and bearish scenarios say about 506260?
What is the P/E ratio of 506260?
How solid is the balance sheet of Anuh Pharma Limited (506260)?
How far is 506260 from its 52-week high?
Which stocks are comparable to Anuh Pharma Limited?
Is Anuh Pharma Limited stock attractive at the current price?
How is the fair value of 506260 calculated?
Is it still worth investing in stocks now?
What is the share price of Anuh Pharma Limited (506260)?
What should I pay attention to with Anuh Pharma Limited right now?
Key figures of Anuh Pharma Limited
How large is the market capitalisation of Anuh Pharma Limited (506260)?
What is the P/S ratio of Anuh Pharma Limited (506260)?
What are the earnings per share of Anuh Pharma Limited (506260)?
What is the dividend yield of Anuh Pharma Limited (506260)?
What is the net margin of Anuh Pharma Limited (506260)?
What is the return on equity of Anuh Pharma Limited (506260)?
What is the EBIT return on assets of Anuh Pharma Limited (506260)?
What is the operating margin of Anuh Pharma Limited (506260)?
How fast is revenue growing at Anuh Pharma Limited (506260)?
How fast are earnings growing at Anuh Pharma Limited (506260)?
How much free cash flow does Anuh Pharma Limited (506260) generate?
How much net debt does Anuh Pharma Limited (506260) carry?
Watch Anuh Pharma Limited in the live analysis
One click puts Anuh Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.